Annexon reports initial Phase 3 FORWARD data for tanruprubart in Guillain-Barré Syndrome

Annexon reported initial outcomes from 6 patients in the pivotal Phase 3 FORWARD study of tanruprubart for Guillain-Barré Syndrome. The data were presented at the World Muscle Society Meeting in Hiroshima.

Detected & updated continuously · Source: Nebula